These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 28770101)

  • 1. Cytokeratin-based assessment of tumour budding in colorectal cancer: analysis in stage II patients and prospective diagnostic experience.
    Koelzer VH; Assarzadegan N; Dawson H; Mitrovic B; Grin A; Messenger DE; Kirsch R; Riddell RH; Lugli A; Zlobec I
    J Pathol Clin Res; 2017 Jul; 3(3):171-178. PubMed ID: 28770101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive assessment of tumour budding by cytokeratin staining in colorectal cancer.
    Rieger G; Koelzer VH; Dawson HE; Berger MD; Hädrich M; Inderbitzin D; Lugli A; Zlobec I
    Histopathology; 2017 Jun; 70(7):1044-1051. PubMed ID: 28061021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relationship between tumour budding, the tumour microenvironment and survival in patients with primary operable colorectal cancer.
    van Wyk HC; Park JH; Edwards J; Horgan PG; McMillan DC; Going JJ
    Br J Cancer; 2016 Jul; 115(2):156-63. PubMed ID: 27299960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumour budding in pancreatic cancer revisited: validation of the ITBCC scoring system.
    Karamitopoulou E; Wartenberg M; Zlobec I; Cibin S; Worni M; Gloor B; Lugli A
    Histopathology; 2018 Jul; 73(1):137-146. PubMed ID: 29495092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Digital image analysis of pan-cytokeratin stained tumor slides for evaluation of tumor budding in pT1/pT2 colorectal cancer: Results of a feasibility study.
    Jepsen RK; Klarskov LL; Lippert MF; Novotny GW; Hansen TP; Christensen IJ; Høgdall E; Riis LB
    Pathol Res Pract; 2018 Sep; 214(9):1273-1281. PubMed ID: 30017334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic value of tumour stroma ratio and tumour budding in stage II colon cancer. A nationwide population-based study.
    Eriksen AC; Sørensen FB; Lindebjerg J; Hager H; dePont Christensen R; Kjær-Frifeldt S; Hansen TF
    Int J Colorectal Dis; 2018 Aug; 33(8):1115-1124. PubMed ID: 29785462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential clinical impacts of tumour budding evaluated by the use of immunohistochemical and haematoxylin and eosin staining in stage II colorectal cancer.
    Yamadera M; Shinto E; Kajiwara Y; Mochizuki S; Okamoto K; Shimazaki H; Hase K; Ueno H
    Histopathology; 2019 Jun; 74(7):1005-1013. PubMed ID: 30698857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumour budding at invasive margins and outcome in colorectal cancer.
    Kanazawa H; Mitomi H; Nishiyama Y; Kishimoto I; Fukui N; Nakamura T; Watanabe M
    Colorectal Dis; 2008 Jan; 10(1):41-7. PubMed ID: 18078460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving tumour budding evaluation in colon cancer by extending the assessment area in colectomy specimens.
    Martinez-Ciarpaglini C; Fernandez-Sellers C; Tarazona N; Roselló S; Huerta M; Roda D; Mongort C; Ferrández A; Navarro S; Cervantes A
    Histopathology; 2019 Oct; 75(4):517-525. PubMed ID: 31081121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour budding is a reproducible index for risk stratification of patients with stage II colon cancer.
    Lai YH; Wu LC; Li PS; Wu WH; Yang SB; Xia P; He XX; Xiao LB
    Colorectal Dis; 2014 Apr; 16(4):259-64. PubMed ID: 24118729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumour budding is a strong and independent prognostic factor in pancreatic cancer.
    Karamitopoulou E; Zlobec I; Born D; Kondi-Pafiti A; Lykoudis P; Mellou A; Gennatas K; Gloor B; Lugli A
    Eur J Cancer; 2013 Mar; 49(5):1032-9. PubMed ID: 23177090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumour budding is associated with the mesenchymal colon cancer subtype and RAS/RAF mutations: a study of 1320 colorectal cancers with Consensus Molecular Subgroup (CMS) data.
    Trinh A; Lädrach C; Dawson HE; Ten Hoorn S; Kuppen PJK; Reimers MS; Koopman M; Punt CJA; Lugli A; Vermeulen L; Zlobec I
    Br J Cancer; 2018 Nov; 119(10):1244-1251. PubMed ID: 30385823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour buds determine prognosis in resected pancreatic ductal adenocarcinoma.
    Lohneis P; Sinn M; Klein F; Bischoff S; Striefler JK; Wislocka L; Sinn BV; Pelzer U; Oettle H; Riess H; Denkert C; Bläker H; Jühling A
    Br J Cancer; 2018 May; 118(11):1485-1491. PubMed ID: 29755112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumour budding as prognostic factor in stage I/II colorectal carcinoma.
    Prall F; Nizze H; Barten M
    Histopathology; 2005 Jul; 47(1):17-24. PubMed ID: 15982319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are tumour grade and tumour budding equivalent in colorectal cancer? A retrospective analysis of 771 patients.
    Zlobec I; Dawson HE; Blank A; Bokhorst JM; Berger MD; Nagtegaal ID; Lugli A
    Eur J Cancer; 2020 May; 130():139-145. PubMed ID: 32200222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of the International Tumor Budding Consensus Conference 2016 recommendations on tumor budding in stage I-IV colorectal cancer.
    Dawson H; Galuppini F; Träger P; Berger MD; Studer P; Brügger L; Zlobec I; Inderbitzin D; Lugli A
    Hum Pathol; 2019 Mar; 85():145-151. PubMed ID: 30428391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor budding in colorectal cancer revisited: results of a multicenter interobserver study.
    Koelzer VH; Zlobec I; Berger MD; Cathomas G; Dawson H; Dirschmid K; Hädrich M; Inderbitzin D; Offner F; Puppa G; Seelentag W; Schnüriger B; Tornillo L; Lugli A
    Virchows Arch; 2015 May; 466(5):485-93. PubMed ID: 25701480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aggressive colorectal carcinoma phenotypes of invasion can be assessed reproducibly and effectively predict poor survival: interobserver study and multivariate survival analysis of a prospectively collected series of 299 patients after potentially curative resections with long-term follow-up.
    Wöhlke M; Schiffmann L; Prall F
    Histopathology; 2011 Nov; 59(5):857-66. PubMed ID: 22092397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined epithelial marker analysis of tumour budding in stage II colorectal cancer.
    Slik K; Blom S; Turkki R; Välimäki K; Kurki S; Mustonen H; Haglund C; Carpén O; Kallioniemi O; Korkeila E; Sundström J; Pellinen T
    J Pathol Clin Res; 2019 Jan; 5(1):63-78. PubMed ID: 30358171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumour budding and CD8
    Georges NDF; Oberli B; Rau TT; Galván JA; Nagtegaal ID; Dawson H; Blank A; Kohler A; Lugli A; Zlobec I
    Histopathology; 2021 Jun; 78(7):1009-1018. PubMed ID: 33340423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.